Related Experiment Video
Updated: Aug 18, 2026

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
Published on: February 7, 2011
Chronic hyperinsulinemia inhibits platelet-activating factor (PAF) biosynthesis in the rat kidney
G B Kudolo1, S J Koopmans, J R Haywood
1Department of Clinical Laboratory Sciences, University of Texas Health Science Center, San Antonio 78274, USA.
Abstract:
A number of risk factors for cardiovascular disease, including hypertension, are associated with the insulin resistance syndrome. The hallmark of this syndrome is an impairment in insulin action which provokes a compensatory increase in pancreatic beta-cell insulin secretion leading to chronic hyperinsulinemia. Indirect studies show that platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine, PAF), a potent antihypertensive lipid produced by the kidney, may be decreased by hyperinsulinemia. The present study was designed to evaluate the effect of chronic hyperinsulinemia on renal PAF metabolism, arterial blood pressure and whole body insulin sensitivity. Chronic catheterized, unstressed rats were infused with saline or insulin plus glucose to create a chronic condition of sustained euglycemic (approximately 130 mg/dl) hyperinsulinemia (approximately 90 mU 1. or 3-fold over basal levels). PAF is a metabolically unstable compound being susceptible to rapid degradation to the biologically inactive lyso-PAF, a metabolite which also serves as a precursor for PAF synthesis. PAF synthesis and counter-regulatory prostaglandins may be derived from the same arachidonate precursor. The enzymes which catalyze these reactions were measured in plasma and in the subcellular fractions of the kidneys. Compared to saline-treated rats, sustained physiologic hyperinsulinemia for 7 days: (i) decreased insulin-mediated glucose disposal by 30%; (ii) caused an increased plasma PAF:acetylhydrolase, which degrades PAF to lyso-PAF, without any change in cytosolic PAF:acetylhydrolase activity; and (iii) completely inhibited microsomal lyso-PAF:acetyl CoA acetyltransferase activity which catalyzes the conversion of lyso-PAF back to bioactive PAF. The increased catabolism of PAF in plasma, combined with decreased renal PAF biosynthesis, would be expected to decrease circulating PAF levels leading to a rise in blood pressure. However, blood pressure remained unchanged. The sustained hyperinsulinemia stimulated plasma membrane CoA-independent transacylase activity, which is responsible for the mobilization of arachidonates into lyso-PAF, to form l-alkylarchidonoyl-glycerophosphocholine. The latter is the stored precursor for the synthesis of PAF and vasodilatory prostaglandins, which may have offset the effect of decreased PAF. We hypothesize that hyperinsulinemia may alter the blood pressure only if the balance between the synthesis/catabolism of PAF and vasodilatory prostaglandins is disrupted.
Insights
Chronic hyperinsulinemia impairs insulin sensitivity and alters platelet-activating factor (PAF) metabolism. This disruption in PAF synthesis and breakdown, alongside prostaglandin activity, may influence blood pressure regulation.
Area of Science:
- Cardiovascular Disease Research
- Metabolic Syndrome Studies
- Lipid Metabolism Research
Background:
- Cardiovascular disease risk factors, including hypertension, are linked to insulin resistance syndrome.
- Insulin resistance syndrome is characterized by impaired insulin action and compensatory hyperinsulinemia.
- Platelet-activating factor (PAF), a kidney-produced lipid, may be reduced by hyperinsulinemia, potentially affecting blood pressure.
Purpose of the Study:
- To investigate the impact of chronic hyperinsulinemia on renal PAF metabolism.
- To assess the effects of hyperinsulinemia on arterial blood pressure.
- To evaluate changes in whole-body insulin sensitivity under hyperinsulinemic conditions.
Main Methods:
- Sustained euglycemic hyperinsulinemia was induced in rats via insulin and glucose infusion.
- Measurements included insulin-mediated glucose disposal, plasma and kidney enzyme activities related to PAF metabolism, and arterial blood pressure.
- Key enzymes analyzed were PAF acetylhydrolase, lyso-PAF acetyltransferase, and transacylase.
Main Results:
- Hyperinsulinemia decreased insulin-mediated glucose disposal by 30%.
- Plasma PAF catabolism increased due to elevated PAF acetylhydrolase, while renal PAF synthesis was inhibited.
- Despite expected blood pressure increases, arterial pressure remained unchanged, potentially due to stimulated transacylase activity and prostaglandin synthesis.
Conclusions:
- Sustained hyperinsulinemia significantly alters PAF metabolism, increasing its degradation and decreasing its synthesis.
- The unchanged blood pressure suggests a compensatory mechanism involving vasodilatory prostaglandins that may offset the effects of altered PAF levels.
- Disruption of the balance between PAF synthesis/catabolism and prostaglandin activity could be critical for hyperinsulinemia-induced blood pressure changes.
Related Concept Videos
Diabetic Nephropathy
Chronic Pancreatitis II: Pathophysiology

